GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

RIGL · Jun 30, 2026

RIGEL PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001034842-26-000052General Corporate

Operating cash generation90thOwn-history percentile · N=10

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

38.95% · OPTIONAL · VALID

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

-22.60% · CORE · NOT_ENOUGH_HISTORY

Inventory pressure60thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

18.25% · OPTIONAL · VALID

Operating margin70thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.operating_margin

29.95% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

17.74% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensity90thOwn-history percentile · N=10

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

8.70% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History7 statesHistory building

Dec 31, 20240/6 normalizedLevel 3 Mar 31, 20250/6 normalizedLevel 3 Jun 30, 20250/6 normalizedLevel 3 Sep 30, 20250/6 normalizedLevel 3 Dec 31, 20255/7 normalizedLevel 3 Mar 31, 20265/7 normalizedLevel 3 Jun 30, 20264/6 normalizedLevel 3

Period transition

What moved in the state?

Cash Generation Increased

Previous: 4.63%
Current: 38.95%
Delta: 34.31%

Growth Decreased

Previous: 10.28%
Current: -22.60%
Delta: -32.89%

Inventory Pressure Decreased

Previous: 19.81%
Current: 18.25%
Delta: -1.56%

Profitability Increased

Previous: 20.21%
Current: 29.95%
Delta: 9.75%

R And D Intensity Decreased

Previous: 19.85%
Current: 17.74%
Delta: -2.11%

Sbc Intensity Increased

Previous: 5.88%
Current: 8.70%
Delta: 2.82%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Compared To · Pharmaceutical Preparations peers →Has State · RIGEL PHARMACEUTICALS INC →Transitioned To · RIGL Fundamental State →Transitioned To · RIGL CASH_GENERATION_INCREASED →Transitioned To · RIGL GROWTH_DECREASED →Transitioned To · RIGL INVENTORY_PRESSURE_DECREASED →Transitioned To · RIGL PROFITABILITY_INCREASED →Transitioned To · RIGL R_AND_D_INTENSITY_DECREASED →Transitioned To · RIGL SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.